Evidence map›Paper›PMID 25694352›Full record

ArticleJournal of neuro-oncology2015

Tumor-specific mutations in low-frequency genes affect their functional properties.

Lale Erdem-Eraslan, Daphne Heijsman, Maurice de Wit, Andreas Kremer, Andrea Sacchetti, Peter J van der Spek, Peter A E Sillevis Smitt, Pim J French

Open access · hybridAbstract read
In one paragraph

Article in Journal of neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Karyopherins in cancer.Current opinion in cell biology · 2018
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Lale Erdem-EraslanDepartment of Neurology, Be 430A, Erasmus Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
Daphne Heijsman
Maurice de Wit
Andreas Kremer
Andrea Sacchetti
Peter J van der Spek
Peter A E Sillevis Smitt
Pim J French
Erasmus MC · NLErasmus University Rotterdam · NLMeertens Institute · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Causal genetic changes in oligodendrogliomas (OD) with 1p/19q co-deletion include mutations in IDH1, IDH2, CIC, FUBP1, TERT promoter and NOTCH1. However, it is generally assumed that more somatic mutations are required for tumorigenesis. This study aimed to establish whether genes mutated at low frequency can be involved in OD initiation and/or progression. We performed whole-genome sequencing on three anaplastic ODs with 1p/19q co-deletion. To estimate mutation frequency, we performed targeted resequencing on an additional 39 ODs. Whole-genome sequencing identified a total of 55 coding mutations (range 8-32 mutations per tumor), including known abnormalities in IDH1, IDH2, CIC and FUBP1. We also identified mutations in genes, most of which were previously not implicated in ODs. Targeted resequencing on 39 additional ODs confirmed that these genes are mutated at low frequency. Most of the mutations identified were predicted to have a deleterious functional effect. Functional analysis on a subset of these genes (e.g. NTN4 and MAGEH1) showed that the mutation affects the subcellular localization of the protein (n = 2/12). In addition, HOG cells stably expressing mutant GDI1 or XPO7 showed altered cell proliferation compared to those expressing wildtype constructs. Similarly, HOG cells expressing mutant SASH3 or GDI1 showed altered migration. The significantly higher rate of predicted deleterious mutations, the changes in subcellular localization and the effects on proliferation and/or migration indicate that many of these genes functionally may contribute to gliomagenesis and/or progression. These low-frequency genes and their affected pathways may provide new treatment targets for this tumor type.

Indexed as

Brain NeoplasmsCell Line, TumorCell MovementCell ProliferationExportin 1 ProteinFemaleGene Expression Regulation, NeoplasticGenome-Wide Association StudyGreen Fluorescent ProteinsGuanine Nucleotide Dissociation InhibitorsHEK293 CellsHumansKaryopherinsMaleMutationNeoplasm Proteinsenhanced green fluorescent proteinExportin 1 ProteinGDP dissociation inhibitor 1Green Fluorescent ProteinsGuanine Nucleotide Dissociation InhibitorsKaryopherinsNeoplasm ProteinsReceptors, Cytoplasmic and NuclearRepressor ProteinsZBTB18 protein, human

Identifiers

PMID25694352
PMCPMC4436689
OpenAlexW2029688300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.